Nxstage Medical, Inc. (NXTM)

[surf1944]

7:14AM Nxstage Medical beats by $0.01, beats on revs; guides Q1 EPS, revs below consensus; guides FY13 EPS below consensus, revs in-line (NXTM) 10.85 : Reports Q4 (Dec) loss of $0.04 per share, $0.01 better than the Capital IQ Consensus Estimate of ($0.05); revenues rose 14.0% year/year to $65 mln vs the $63.54 mln consensus.

Co issues downside guidance for Q1, sees EPS of ($0.09)-(0.08) vs. ($0.05) Capital IQ Consensus Estimate; sees Q1 revs of $60.5-62.0 mln vs. $63.85 mln Capital IQ Consensus Estimate.

Co issues guidance for FY13, sees EPS of ($0.28)-(0.22) vs. ($0.11) Capital IQ Consensus Estimate; sees FY13 revs of $265-270 mln vs. $268.95 mln Capital IQ Consensus Estimate.

"Taken together with increasing confidence in our ability to drive continued growth with new direct to patient marketing programs, we believe the overall effect of our product execution is that we are better positioned to accelerate adoption of our therapies with much greater potential than in the past. With the benefit of these programs largely expected in 2014, we expect top line 2013 revenue to remain strong and grow at a rate similar with 2012, followed by accelerated success and over 15% annual revenue growth in 2014 and beyond, excluding any benefit of service revenue from NxStage owned centers of excellence.